Zhejiang Medicine Signs Long-Term Supply Contract With Hospira
This article was originally published in PharmAsia News
Zhejiang Medicine has signed a supply contract with Hospira, an American specialty pharmaceutical and medication delivery company. Under the agreement, Zhejiang Medicine will provide Hospira vancomycin hydrochloride raw materials from April 30, 2008 to Dec. 31, 2017, with an expected total amount of $120 million. Taking into consideration the fluctuating Chinese yuan renminbi and U.S. dollar exchange rate, both sides have decided on the May 1, 2007 rate of $1 to 7.7 yuan as a benchmark. However, if the fluctuation exceeds 10 percent and lasts 90 days, both sides will adjust the value according to the new exchange rate at that point in time. (Click her for more - Chinese language)
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.